PCM
HARP

Penserra Capital Management’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Penserra Capital Management’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-75
Closed -$5K – 1610
2021
Q3 		$5K Buy
75
+1
+1% +$101 ﹤0.01% 1416
2021
Q2 		$10K Buy
74
+1
+1% +$191 ﹤0.01% 1276
2021
Q1 		$15K Buy
73
+13
+22% +$2.61K ﹤0.01% 996
2020
Q4 		$9K Buy
+60
New +$9.27K ﹤0.01% 941

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Penserra Capital Management's HARP Position: Q4 2021 in Review

Penserra Capital Management sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q4 2021, closing a stake of 75 shares — an estimated $5K sold.

Penserra Capital Management first reported a position in HARP in Q4 2020 and held it in 4 quarters. The position peaked at $15K in Q1 2021. 84 funds tracked by Wall St. Rank hold HARP as of Q4 2021.

  • Penserra Capital Management reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 75 Harpoon Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $5K.
  • Penserra Capital Management first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Harpoon Therapeutics, Inc. Common Stock position peaked at $15K in Q1 2021.
  • 84 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.